St Louis, MONCT07636811Now EnrollingIRB Ready

Down Syndrome-Associated Alzheimer's Disease (DS-AD) Clinical Trial in St Louis, MO

Access cutting-edge down syndrome-associated alzheimer's disease (ds-ad) treatment through this phase 2 clinical trial at a research site in St Louis. Study-provided care at no cost to qualified participants.

Sponsored by Alnylam Pharmaceuticals

Quick Self-Assessment

See if you qualify for this St Louis location

Preparing your pre-screening questions…

Expert Care in St Louis

Access down syndrome-associated alzheimer's disease (ds-ad) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related down syndrome-associated alzheimer's disease (ds-ad) treatment provided free

Apply for This St Louis Location

Check if you qualify for this down syndrome-associated alzheimer's disease (ds-ad) clinical trial in St Louis, MO

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to St Louis

    Convenient for MO residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit St Louis site if eligible
  4. 4Begin participation

About This Down Syndrome-Associated Alzheimer's Disease (DS-AD) Study in St Louis

The purpose of the study is to evaluate the effect of mivelsiran in adult participants with early-stage DS-AD and to characterize the safety, tolerability, and pharmacodynamics (PD) of mivelsiran. The study will be conducted over 2 periods: a 24-month double-blind period and an optional 12-month open-label treatment extension (OLE) period. The estimated duration of study participation, inclusive of screening, treatment, and additional safety follow-up, is up to 39 months.

Sponsor: Alnylam Pharmaceuticals

Who Can Participate

Inclusion Criteria

Clinical diagnosis of Down-Syndrome (DS) associated with trisomy 21
Positive amyloid PET scan
Cognitively stable in the opinion of the investigator
Seizures must be well controlled with no occurrence of seizures in the 6 months prior to screening

Exclusion Criteria

Has severe intellectual disability (ID)
Has a history of DS regression disorder
Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>2×upper limit of normal (ULN) at Screening
Has estimated glomerular filtration rate (eGFR) \<45 mL/min/1.73m\^2 at Screening
Has recently received an investigational agent
Has had treatment with amyloid-targeting antibody
Comorbidities such as obstructive sleep apnea and hypothyroidism that are not well controlled Note: other protocol defined inclusion / exclusion criteria apply

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in St Louis?

Yes, this clinical trial (NCT07636811) has an active research site in St Louis, MO that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Down Syndrome-Associated Alzheimer's Disease (DS-AD) Treatment Options in St Louis, MO

If you're searching for down syndrome-associated alzheimer's disease (ds-ad) treatment options in St Louis, MO, this clinical trial (NCT07636811) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our St Louis research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced down syndrome-associated alzheimer's disease (ds-ad) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all down syndrome-associated alzheimer's disease (ds-ad) clinical trials near you to find additional studies recruiting in your area.

More Alzheimers Disease Trials in St Louis, MO

See all alzheimers disease clinical trials recruiting in St Louis — not just this study.

Browse Alzheimers Disease Trials in St Louis →

Ready to Join in St Louis?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · St Louis, MO